Home >> About

News & Events

Ten years ago, Temple University established the Moulder Center for Drug Discovery Research as a hub for further developing the scientific discoveries of faculty members and scientists. The goals of the centers included facilitating collaboration opportunities with pharmaceutical industry partners and other academic researchers, and moving discoveries made on campus into the broader research community. Now a decade later, the center has generated a measurable return on Temple's investment, The center has spun out one company, and is in the process of launching three more. Its researchers have received 12 patents, filed for more than 30, and obtained more than $7 million in grants and research contracts.

The Moulder Center for Drug Discovery Research was highlighted in Speciality Chemicals Magazine in an article entitled "A Fully Integrated Academic Drug Discovery Center."

Abu Dhabi, United Arab Emirates - Magid Abou-Gharbia served as one of three keynote speakers at the 4th annual Middle East Molecular Biology Congress and Exhibition held under the patronage of H.E. Sheikha Lubna Bint Khalid Al Qasimi  at the Zayed University Convention Center.

Dr. Wendy B. Young, Vice President of Discovery Chemistry, Genentech presented a lecture entitled "From Bench to Clinic: Potent, Selective and Reversible BTK Inhibitors" at Temple University School of Pharmacy

Washington, DC - As part of the American Chemical Society's fall 2017 natioanl meeting, Magid Abou-Gharbia served as one of three participants in the Pharma Leaders Symposium entitled “Working together to make a difference.” 

NEW YORK, June 01, 2017 (GLOBE NEWSWIRE) -- Mid Atlantic Bio Angels (MABA) announces today that Recensa Therapeutics (http://www.recensatherapeutics.com), which is developing a topical psoriasis treatment designed to reduce oxidative stress, was named “Best in Show” by the audience and “Most Fundable” by the investor panel at MABA's 1st Pitch Life Science event held on May 25, 2017 at Rockefeller University in New York City.

May 31st, 2017: Dr Magid Abou-Gharbia chairs Pharma Outsourcing Best Practices Panel at 2017 ChemSpec Europe Meeting at the Munich Trade Fair Center, Germany. 

Dr.Benjamin E Blass and Dr. Daniel J Canney received grant from the Crohn's & Colitis Foundation to study the role of the 5-HT7 receptor in inflammatory bowel disease (IBD).  The three year, $347,490 program entitled “Novel Therapies for the Treatment of Ulcerative Colitis: 5-HT7 Antagonists" will also include Dr. Waliul Khan from McMaster University. Dr. Khan is a leading expert in IBD animal models and pharmacology.

Magid Abou-Gharbia presents keynote address at the 2017 CPhI Connect Conference. His lecture highlighted the issues that face the pharmaceutical industry and possible opportunities to address industry challenges in a changing regulatory and political environment.

Philadelphia, PA February 2, 2017 - A startup emerging from Temple University's School of Pharmacy builds on the work of two of its medicinal chemists and could potentially change the way inflammatory bowel disease is treated.  The company, Praeventix, is advancing a discovery made by the School of Pharmacy’s Daniel Canney and Benjamin Blass of the Moulder Center for Drug Discovery Research.


Temple University
Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140